(12) PATENT (11) Application No. AU 200128277 B2 (19) **AUSTRALIAN PATENT OFFICE** (10) Patent No. 767933 (54)Title Device for injection of antiparasitic agents in pets $(51)^7$ International Patent Classification(s) A61M 005/46 A61K 009/00 A61D 007/00 Application No: 200128277 (22)Application Date: 2000.12.04 (21) WIPO No: WO01/39822 (87)(30)Priority Data (33) Country (31)Number (32) Date 99123948 1999.12.03 **EP** (43)Publication Date: 2001.06.12 Publication Journal Date: 2001.08.23 (43)(44)Accepted Journal Date: 2003.11.27 (71) Applicant(s) **Udo Mattern** (72)Inventor(s) Claudia Mattern (74)Agent/Attorney WATERMARK PATENT and TRADEMARK ATTORNEYS, Locked Bag 5, HAWTHORN VIC 3122 (56)Related Art WO 96/21427 EP 836851

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum Internationales Büro





(43) Internationales Veröffentlichungsdatum 7. Juni 2001 (07.06.2001)

(10) Internationale Veröffentlichungsnummer WO 01/39822 A1

(51) Internationale Patentklassifikation7: A61D 7/00, A61K 9/00

A61M 5/46.

(74) Anwalt: WINKLER, Andreas: Boehmert & Boehmert,

(21) Internationales Aktenzeichen:

PCT/DE00/04316

(22) Internationales Anmeldedatum:

4. Dezember 2000 (04.12.2000)

(25) Einreichungssprache:

Deutsch

(26) Veröffentlichungssprache:

Deutsch

3. Dezember 1999 (03.12.1999)

(30) Angaben zur Priorität: 99123948.4

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): MATTERN, Udo [DE/CH]; Obere Spichermatt 47, CH-6370 Stans (CH).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): MATTERN, Claudia [DE/CH]; Obere Spichermatt 47, CH-6370 Stans (CH).

Holleralice 32, 28209 Bremen (DE).

(81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM. HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK. LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX. MZ. NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL. TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Bestimmungsstauten (regional): ARIPO-Patent (GH. GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Veröffentlicht:

Mit internationalem Recherchenbericht.

Zur Erklärung der Zweibuchstaben-Codes, und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

(54) Title: DEVICE FOR INJECTION OF ANTIPARASITIC AGENTS IN PETS

(54) Bezeichnung: VORRICHTUNG ZUR INJEKTION VON ANTIPARASITIKA BEI HAUSTIEREN

(57) Abstract: The invention relates to a device for the injection of an agent formulation in pets. Said device comprises an injection device, which is so arranged that the injection needle pierces the upper skin layer, but not the lower skin layer and an agent formulation with an antiparasitically effective agent in a formulation which is suitable for injection.

(57) Zusammenfassung: Vorrichtung zur Injektion einer Wirkstofformulierung bei Haustieren, wobei, die Vorrichtung eine Injektionsvorrichtung, die so ausgelegt ist, dass die Injektionsnadel die oberen, aber nicht durch die unteren Hautschichten durchdringt, und eine Wirkstofformulierung mit einem anti-parasitisch wirksamen Wirkstoff in einer zur Injektion geeigneten Formulierung umfasst.



APPARATUS FOR INJECTING ANTIPARASITICS IN DOMESTIC ANIMALS

The invention relates to a method for the prophylaxis or treatment of a parasitic infection in a domestic animal using an apparatus for the application or administration of antiparasitic substances to domestic animals. The invention more particularly relates to the use of an injection device for injectable, antiparasitically acting medicinal substances enabling the latter to be applied intradermally.

EP 897 728 A1 discloses an injection device in the form of a pin, with which an adjustable liquid quantity present in a storage container in the pin, is removed from the latter by moving a pushbutton in the longitudinal direction of the pin and can be injected into a living being through a cannula. The disclosure more particularly deals with a reliable retention of the storage container, for example a medicament phial, and the construction of the adjustable dosing device.

US patent 5,964,731 discloses a retention support for a lancet or hypodermic needle, which makes it possible for the part appropriate for perforation to project from a sleeve and then be retracted into the sleeve again after use. In addition, the part suitable for perforation is covered in the retracted position by a cover located within the sleeve. According to this disclosure the cover, which is inverted over the needle or lancet retracted into the sleeve after use, is designed in such a way that said process is irreversible and the device cannot be used a second time.

WO 99/27984 discloses an injection device for medical use with which in particular pasty fluids can be pressed by means of an electric drive out of the storage cylinder by a plunger and can be supplied to a hypodermic needle.

Known injection devices are suitable for the injection of liquid or pasty medicinal substance formulations, the dose being adjustable or can be fixed by the construction. The in each case disclosed lengths of the hypodermic needles are suitable for intramuscular or intravenous injection. As opposed to this, the present invention proposes a planned injection of the substance formulation in specific skin layers directly below the skin surface of the animal.

Antiparasitic substances are administered either orally/intramuscularly to animals, or are applied externally to the skin. Externally applied, antiparasitic

15

10

5

25

30

substances can diffuse through the skin layers of the animal and are subsequently systemically distributed within the animal, provided that they have a relatively low molecular weight, are sufficiently lypophilic and are applied in a formulation with permeation-increasing substances, such as for example 2-dimethyl sulphoxide, 2-pyrrolidone, ethanol, urea, etc. as sorption providing agents.

5

10

15

25

30

A disadvantage of external application is that the antiparasitic substance must be formulated with a large proportion of sorption providing agent in order to render permeable for the active substance the diffusion barrier of the skin and as a result the natural skin function is destroyed. In addition, in the case of external application the formulation must be used in excess, because only a proportion of the antiparasitic substance applied actually diffuses through the skin and the remaining part is passed into the environment as a pollutant and without having any effect on the animal. The essential factors influencing the proportion of the applied, antiparasitic formulation diffusing into the skin layer are the specific state of the treated skin region, ie the specific characteristics of a particular body area, the age and moistness of the skin and the individually differing characteristics of the skin. It is therefore difficult to estimate for a particular animal the quantity of the antiparasitic formulation necessary for obtaining the appropriately absorbed dose of the antiparasitic substance.

In view of this prior art, the problem of the present invention is to provide an apparatus enabling an antiparasitic substance to be administered to an animal in a reliably constant or adjustable dosage.

The solution provided by the inventive method is to offer a combination of an injection device with an antiparasitic substance in a formulation suitable for injection. In particularly preferred manner the injection device is of the pin type and the delivered active substance formulation quantity can be dosed. It is also important for the present invention that the penetration depth of the hypodermic needle in the injection device is dimensioned in such a way that the active substance formulation is only injected directly below the top skin layers and reaches the lower skin regions, but is not injected into the subcutaneous adipose or muscle tissue. Thus, as a possible embodiment are suitable injection devices of the pin type, in which the available hypodermic needle length only projects

from the pin casing by three, preferably two and in particularly preferred manner 1mm, so that the hypodermic needle penetration depth is predetermined by the actual apparatus.

The antiparasitic substance formulation suitable for injection preferably only contains a small proportion of adjuvants, such as for example resorption providers, so that even a small amount of antiparasitic formulation is adequate for administering an adequate antiparasitic agent dose. Preference is given to antiparasitic formulations, in which the antiparasitic agent is suitable for injection into an animal and which is also contained in a small formulation volume. Particular preference is given to formulations, where there is an adequate antiparasitic agent dose necessary per kilogram of animal weight in a volume of 100, preferably 50 and in particularly preferred manner 10 μ l.

5

15

25

30

The dosage of the antiparasitic formulation can be performed with the apparatus combination of the invention in such a way that the quantity administered per injection pulse can be adjusted to the animal weight, for example by a dosing device according to EP 897 728, or the constructionally fixed dosing volume of the injection device is dimensioned in such a way that it is fixed for 1, 2 or preferably 5 kg of animal weight and by multiple injections of the same formulation volume, it is possible to determine the antiparasitic formulation dose.

The apparatus which is used according to the inventive method, comprises a combination of an injection device and an antiparasitic substance in a suitable formulation and is firstly characterised by a precise, reproducible dosage of the formulation, because there are no losses due to premature evaporation or inadequate sorption by the skin. It is also possible for the apparatus used according to the inventive method to be safely used by non-medical practitioners, because the injection device only permits a limited hypodermic needle penetration depth, so that there is only a very limited injury risk for the animal.

It is particularly advantageous that the present invention obviates the use of large proportions of sorption providers in the active substance formulation and therefore avoids the undesired effects thereof.

The invention also makes it possible to incorporate into the formulation antiparasitic substances which, as a result of their solubility and/or inadequate

lipophilicity or high molecular weight, are unsuitable for external application and sorption through the skin.

The invention also makes it possible to inject specific formulations into the skin layers of the animal which act as a depot for the antiparasitic substance.

It is clear to the expert that there can be various combinations and subcombinations of an injection device and an antiparasitic substance formulation which lead to the apparatus suitable for the inventive method.

5

Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

- 1. A method for the prophylaxis or treatment of a parasitic infection in a domestic animal, the method comprising injecting the animal with an antiparasitically active substance in a formulation suitable for injection purposes, by means of an apparatus comprising the active substance and an injection device designed in such a way that the hypodermic needle penetrates the upper, but not the lower, skin layers.
- 2. Method according to claim 1, characterised in that the hypodermic needle penetration depth is max 3mm.
- 3. Method according to claim 1, characterised in that the hypodermic needle penetration depth is max 2mm.
- 4. Method according to claim 1, characterised in that the hypodermic needle penetration depth is max 1mm.
- 5. Method according to any one of claims 1 to 4, characterised in that the injection device can deliver a fixed active substance formulation volume.
- 6. Method according to any one of claims 1 to 4, characterised in that the injection device has an adjustable dosing mechanism.





7. Method according to any one of the preceding claims, characterised in that the injectable active substance formulation contains an antiparasitic substance from the group comprising IGR chitin synthesis inhibitors, phosphoric acid esters, carbamates, pyrethrum and pyrethroids, avermectins, benzimidazoles, phenothiazines and praziquantel.

DATED this 24th day of March 2003 **UDO MATTERN**

WATERMARK PATENT & TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA

CJS/JMN/RJT